

<!--StartFragment-->RESULT 7  
AAW21921  
ID AAW21921 standard; peptide; 10 AA.  
XX  
AC AAW21921;  
XX  
DT 14-JAN-1998 (first entry)  
XX  
DE Smooth muscle fibre proliferation inhibitor peptide 11.  
XX  
KW Generic; TFPI; inhibitor; proliferation; smooth muscle cell; prevention;  
KW treatment; arteriosclerosis; restenosis; angioplasty; luminal stenosis;  
KW vascular transplantation; leiomyosarcoma; human.  
XX  
OS Synthetic. *US Patent 6,191,113 B1*  
XX  
PN WO9715598-A1.  
XX  
PD 01-MAY-1997. *Japanese*  
XX  
PF 23-OCT-1996; 96WO-JP003080.  
XX  
PR 24-OCT-1995; 95JP-00300792.  
XX  
PA (KAGA ) CHEMO-SERO-THERAPEUTIC RES INST.  
XX  
PI Nakahara Y, Hara S, Kamikubo Y, Takemoto S, Miyamoto S;  
XX  
DR WPI; 1997-258960/23.  
XX  
PT Peptide(s) comprising basic rich peptide bound at C-terminal to  
PT consecutive hydrophobic rich peptide - useful for inhibiting smooth  
PT muscle fibre cell proliferation.  
XX  
PS Example 3; Page 14; 45pp; Japanese.  
XX  
CC Novel peptides contain: (a) a peptide sequence (P1) rich in basic amino  
CC acid residues (preferably lysine, arginine or histidine); and (b) a  
CC peptide sequence (P2) containing at least two consecutive hydrophobic  
CC amino acid residues (preferably phenylalanine, isoleucine, leucine,  
CC methionine, proline, valine, tryptophan or tyrosine); where P2 is bound  
CC to the C-terminal end of P1 either directly or through a linker sequence  
CC of several amino acid residues. The peptides inhibit proliferation of  
CC smooth muscle cells, and are useful in the prevention and treatment of  
CC arteriosclerosis associated with smooth muscle cell proliferation,  
CC restenosis after angioplasty, luminal stenosis after vascular  
CC transplantation, and leiomyosarcoma. AAW21913-29 are specific inhibitory  
CC peptides  
XX  
SQ Sequence 10 AA;

Query Match 100.0%; Score 30; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 92;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KRKRKK 6  
|||  
Db 4 KRKRKK 9

&lt;!--EndFragment--&gt;

SEQ ID NO: 11

Selwood et al.

<!--StartFragment-->RESULT 4  
 AAU98389  
 ID AAU98389 standard; peptide; 7 AA.  
 XX  
 AC AAU98389;  
 XX  
 DT 24-SEP-2002 (first entry)  
 XX  
 DE Synthetic vascular endothelial growth factor (VEGF) peptide #8.  
 XX  
 KW Vascular endothelial growth factor; VEGF; angiogenesis inhibitor; cancer;  
 KW eye angiogenic disease; diabetic retinopathy; ARDS; skin disease;  
 KW age-related macular degeneration; tumour growth; endometriosis;  
 KW psoriasis; Kaposi's sarcoma; acquired immunodeficiency syndrome; AIDS;  
 KW malignant melanoma; solid malignant tumour; ovary; breast; lung;  
 KW pancreas; prostate; colon; epidermoid cancer; rheumatoid arthritis;  
 KW inflammatory condition.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200234767-A1.  
 XX  
 PD 02-MAY-2002.  
 XX  
 PF 25-OCT-2001; 2001WO-GB004736.  
 XX  
 PR 25-OCT-2000; 2000GB-00026134.  
 XX  
 PA (ARKT-) ARK THERAPEUTICS LTD.  
 XX  
 PI Selwood D, Zachary I, Jia H, Loehr M, Davis D;  
 XX  
 DR WPI; 2002-527413/56.  
 XX  
 PT Peptide which is a fragment of vascular endothelial growth factor, and  
 PT which inhibits angiogenesis, useful for treating psoriasis, rheumatoid  
 PT arthritis, endometriosis, and cancer.  
 XX  
 PS Disclosure; Fig 2; 23pp; English.  
 XX  
 CC The present invention relates to a new peptide which is a fragment of  
 CC vascular endothelial growth factor (VEGF) and which inhibits  
 CC angiogenesis. The peptide of the invention has therapeutic uses. It is  
 CC useful for the manufacture of a medicament for inhibiting angiogenesis  
 CC and for manufacture of a medicament for treating cancer. The invention is  
 CC also useful for treating angiogenic diseases of the eye such as diabetic  
 CC retinopathy, or diseases where angiogenesis might be implicated such as  
 CC ARDS (age-related macular degeneration). Other diseases where  
 CC angiogenesis may play a significant role are in tumour growth, or in  
 CC endometriosis, and diseases of the skin such as psoriasis. The peptides  
 CC may also be useful in the treatment of specific cancers, including  
 CC Kaposi's sarcoma (which occurs in acquired immunodeficiency syndrome  
 CC (AIDS) patients), malignant melanoma of the skin and eye, and solid  
 CC malignant tumours of ovary, breast, lung, pancreas, prostate, colon and  
 CC epidermoid cancers. They may also be used in the treatment of rheumatoid  
 CC arthritis as an inflammatory condition with a vascular component. The  
 CC present amino acid sequence represents one of a collection (AAU98382-  
 CC AAU98400 and AAU99251-AAU99252) of VEGF peptides of the invention  
 XX  
 SQ Sequence 7 AA;

Query Match 100.0%; Score 6; DB 5; Length 7;  
Best Local Similarity 100.0%; Pred. No. 2.3e+06;  
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KRKRKK 6  
| | | | |  
Db 2 KRKRKK 7

<!--EndFragment-->

<!--StartFragment-->RESULT 12  
A41551  
vascular endothelial growth factor 206 precursor - human  
N;Alternate names: vascular permeability factor  
N;Contains: vascular endothelial growth factor 121 (VEGF 121); VEGF 165; VEGF 189; VEG  
C;Species: Homo sapiens (man)  
C;Date: 28-Aug-1992 #sequence\_revision 28-Aug-1992 #text\_change 05-Nov-1999  
C;Accession: A41551; C41551; B41551; A40454; B40454; C40454; A40079; A40080; JQ1463; J  
R;Houck, K.A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D.W.  
Mol. Endocrinol. 5, 1806-1814, 1991  
A;Title: The vascular endothelial growth factor family: identification of a fourth mol  
A;Reference number: A41551; MUID:92168017; PMID:1791831  
A;Accession: A41551  
A;Molecule type: mRNA  
A;Residues: 1-232 <HOU1>  
A;Cross-references: UNIPARC:UPI0000030866; GB:S85192; NID:g246155; PID:g246156  
A;Accession: C41551  
A;Status: nucleic acid sequence not shown  
A;Molecule type: mRNA  
A;Residues: 1-140,'N',183-232 <HOU2>  
A;Cross-references: UNIPARC:UPI0000001243  
A;Accession: B41551  
A;Status: nucleic acid sequence not shown; not compared with conceptual translation  
A;Molecule type: mRNA  
A;Residues: 1-141,227-232 <HOU>  
A;Cross-references: UNIPARC:UPI0000001243  
R;Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J.C.;  
J. Biol. Chem. 266, 11947-11954, 1991  
A;Title: The human gene for vascular endothelial growth factor. Multiple protein forms  
A;Reference number: A40454; MUID:91268072; PMID:1711045  
A;Accession: A40454  
A;Molecule type: DNA  
A;Residues: 1-165,183-232 <TI1>  
A;Cross-references: UNIPARC:UPI000002B6AA; GB:M63971; GB:M63972; GB:M63973; GB:M63974;  
A;Accession: B40454  
A;Molecule type: DNA  
A;Residues: 1-140,'N',183-232 <TI2>  
A;Cross-references: UNIPARC:UPI0000001243; GB:M63971; GB:M63972; GB:M63973; GB:M63974;  
A;Accession: C40454  
A;Molecule type: DNA  
A;Residues: 1-141,227-232 <TI3>  
A;Cross-references: UNIPARC:UPI0000030864; GB:M63971; GB:M63972; GB:M63973; GB:M63974;  
R;Keck, P.J.; Hauser, S.D.; Krivi, G.; Sanzo, K.; Warren, T.; Feder, J.; Connolly, D.T  
Science 246, 1309-1312, 1989  
A;Title: Vascular permeability factor, an endothelial cell mitogen related to PDGF.  
A;Reference number: A40079; MUID:90069609; PMID:2479987  
A;Accession: A40079  
A;Status: not compared with conceptual translation  
A;Molecule type: mRNA  
A;Residues: 1-165,183-232 <KEC>  
A;Cross-references: UNIPARC:UPI000002B6AA; GB:M27281; NID:g340300; PIDN:AAA36807.1; PI  
R;Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N.  
Science 246, 1306-1309, 1989  
A;Title: Vascular endothelial growth factor is a secreted angiogenic mitogen.  
A;Reference number: A40080; MUID:90069608; PMID:2479986  
A;Accession: A40080  
A;Status: not compared with conceptual translation  
A;Molecule type: mRNA  
A;Residues: 1-140,'N',183-232 <LEU>  
A;Cross-references: UNIPARC:UPI0000001243; GB:M32977; NID:g181970; PIDN:AAA35789.1; PI  
R;Weindel, K.; Marne, D.; Weich, H.A.

Biochem. Biophys. Res. Commun. 183, 1167-1174, 1992  
A;Title: AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelia  
A;Reference number: JQ1463; MUID:92231879; PMID:1567395  
A;Accession: JQ1463  
A;Molecule type: mRNA  
A;Residues: 1-140, 'N', 183-232 <WE1>  
A;Cross-references: UNIPARC:UPI0000001243; EMBL:X62568; NID:g37658; PIDN:CAA44447.1; P  
A;Experimental source: AIDS-Kaposi's sarcoma cell  
A;Accession: JQ1464  
A;Molecule type: mRNA  
A;Residues: 1-140, 'N', 227-232 <WE2>  
A;Cross-references: UNIPARC:UPI000002B6AE  
A;Experimental source: AIDS-Kaposi's sarcoma cell  
R;Connolly, D.T.; Olander, J.V.; Heuvelman, D.; Nelson, R.; Monsell, R.; Siegel, N.; H  
J. Biol. Chem. 264, 20017-20024, 1989  
A;Title: Human vascular permeability factor. Isolation from U937 cells.  
A;Reference number: A34492; MUID:90062112; PMID:2584205  
A;Accession: A34492  
A;Molecule type: protein  
A;Residues: 27-36; 43-49, 'R'; 72-76, 'Q', 78-81; 59-71 <CON>  
A;Cross-references: UNIPARC:UPI000017C411; UNIPARC:UPI000017C412; UNIPARC:UPI000017C41  
C;Comment: The most common of several alternatively spliced forms is VEGF 165.  
C;Genetics:  
A;Gene: GDB:VEGF  
A;Cross-references: GDB:132244; OMIM:192240  
A;Map position: 6p21-6p12  
C;Function:  
A;Description: promotes fluid and protein leakage from blood vessels  
C;Keywords: alternative splicing; angiogenesis; dimer; disulfide bond; extracellular p  
F;1-232/Product: vascular endothelial growth factor 206 precursor #status predicted <V  
F;1-165,183-232/Product: vascular endothelial growth factor 189 precursor #status pred  
F;1-141,227-232/Product: vascular endothelial growth factor 121 precursor #status pred  
F;1-26/Domain: signal sequence #status predicted <SIG>  
F;101/Binding site: carbohydrate (Asn) (covalent) #status predicted

```

Query Match          100.0%;  Score 30;  DB 2;  Length 232;
Best Local Similarity 100.0%;  Pred. No. 1.3e+02;
Matches       6;  Conservative    0;  Mismatches    0;  Indels      0;  Gaps       0;

Qy           1 KRKRKK 6
            ||||| |
Db        152 KRKRKK 157

```

&lt;!--EndFragment--&gt;